As a leading global forum for advancing efforts to end tuberculosis and improve lung health, the Union Conference brings together researchers, health professionals, advocates and policymakers to share the latest evidence, innovations and experiences from across the world. It provides an important platform for shaping the global health agenda, strengthening collaboration and accelerating progress towards better prevention, diagnosis and treatment of TB and other lung diseases.
For Unitaid, the Union Conference is an opportunity to engage with partners, highlight progress in bringing innovative TB tools and approaches closer to the people who need them, and contribute to discussions on how to accelerate their introduction and access. Through our work with partners, we support efforts to make new and improved tools available, affordable and accessible, particularly in the countries and communities most affected by TB.

With 2030 rapidly approaching, the WHO Global End TB Symposium 2026 will focus on the urgent actions needed to accelerate progress, strengthen political engagement, drive multisectoral action and translate global commitments into results, while harnessing the power of new innovations and breakthroughs to transform the fight against TB.
Bringing together countries, partners, civil society, affected communities, researchers and other stakeholders, the Symposium will present key findings from the newly released WHO Global Tuberculosis Report 2026, taking stock of the latest trends and progress towards global TB targets. It will also spotlight the latest advances and breakthroughs in TB prevention, diagnosis and treatment, and explore how innovations and new technologies can be rapidly and equitably translated into greater impact for people and communities affected by TB.
At this critical juncture, the Symposium will also look beyond 2030, providing a platform to discuss the priorities and transformative approaches that should shape the WHO post-2030 global TB strategy and the next era of the global TB response. The Symposium will call for renewed political leadership, sustained investment, stronger partnerships and multisectoral action to deliver on commitments, accelerate progress to 2030, and drive the transformative change needed to advance global efforts to end TB.
Phenotypic drug susceptibility testing (pDST) remains the reference standard for defining drug resistance and guiding tuberculosis treatment, yet global capacity is declining and methods remain insufficiently standardized. Recent multi-country efforts to validate broth microdilution (BMD) platforms and generate minimum inhibitory concentration (MIC) data offer an opportunity to harmonize testing and interpretation. This symposium will position pDST as a critical complement to genomic testing, highlighting its role in defining resistance, supporting WHO mutation catalogue development, and informing treatment decisions. Through implementation- and evidence-focused presentations, including insights from clinical studies and global initiatives, speakers will identify key priorities to strengthen laboratory systems and support the future of DR-TB care.
Shaping the future of DR-TB care: The role of phenotypic DST in access, innovation and scale-up
Organised by: DeepTek.ai
To bring together global health partners and national TB programmes to explore what it takes to move AI-powered TB screening from innovation to routine practice at scale. Through perspectives from market-shaping organizations and countries at different stages of AI adoption, the session will examine the practical enablers of equitable access—including affordability, financing, procurement, implementation, health system integration, and sustainable market mechanisms—and identify actionable strategies to accelerate the adoption of quality-assured AI technologies for TB elimination.
Catalysing equitable access to AI for TB: From innovation to sustainable scale
Speaker: Dessie Tarlton
Organised by: PATH, Unitaid, World Health Organization, Global Coalition of TB Advocates
The global tuberculosis (TB) response is in a pivotal period. With new vaccine candidates and shorter treatment regimens on the horizon and decentralized diagnostics and AI-enabled technologies being introduced, the pipeline of TB innovations is rich and advancing rapidly. The challenge, however, lies in how countries can sustainably introduce, integrate, and scale these innovations to accelerate progress toward 2030 global targets while ensuring equitable and inclusive access to people-centered TB care.
Framed by an overview of progress towards 2030 targets and a state-of-play of emerging TB innovations, this session will convene government leaders, civil society, affected communities, researchers, funders, and implementers to share learnings on sustainably introducing product and service innovations through primary health care platforms and concluding with a dynamic discussion delving into challenges and practical solutions for community-driven and resilient roll out and scale of critical new tools and care models that accelerate people-centered approaches to end TB.
Innovation pipeline: what’s here, what’s coming and what that means for sustained access
Speaker: Jérémie Piton
This session aims to move beyond a focus on innovative financing mechanisms to explore how countries can practically finance high-impact tuberculosis (TB) interventions at scale. It will focus on how financing decisions influence programme delivery, particularly for interventions such as active case finding, private sector engagement, diagnostics, and prevention, which are often underfunded within existing systems.
Background and Rationale:
Despite global commitments to end TB, many high-impact interventions remain underfunded or inconsistently financed. The challenge is not only the overall level of funding, but how resources are allocated within national programmes. Previous discussions on innovative financing have largely focused on instruments (e.g. development bank loans, debt swaps, philanthropy), with less attention to how these translate into programmatic decisions at country level. This session builds on that foundation and shifts the focus towards implementation, specifically how countries can align financing withi nterventions that drive impact.
Market stewardship during transitions